Biotech "Tweets of the Week"
March Madness
(March 14-18, 2016)
Headlines - $CBAY $CPXX $GWPH $VRX $VTAE
In the News - $AMGN $CBAY $EGRX $GILD $LLY $OREX $REGN $RLYP $SNY $SRPT
$XBI $IBB $LABU #AACR16
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
GW Pharma's "pot drug" shines in key epilepsy trial $GWPH
$GWPH GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex® (cannabidiol) https://t.co/6BIk65PoJ8 cc: @JasonCRG
— Joe (@GantosJ) March 14, 2016
@bradloncar 10 of 61 patients experienced SAE's, and 8 discontinued... amazing move up 92% though
— Shane Blackmon (@shaneblackmon) March 14, 2016
Is it irony that my music shuffle turned up Dylan's "Rainy Day Women #12 & 35" 1st thing today? Everybody must get stoned. $GWPH
— Jon Gardner (@ByJonGardner) March 14, 2016
GW Pharma Marijuana Drug Cuts Seizure Rate in Pivotal Study https://t.co/DLARoJjAWB $GWPH
— Adam Feuerstein (@adamfeuerstein) March 14, 2016
Whether you were long short or neither on $GWPH the #biotech sector really needed this shot in the arm
— Dan Rosenblum (@sharkbiotech) March 14, 2016
$GWPH really not that many shares traded for the 130% increase.. retail at work
— Julia Skripka-Serry (@JuliaSkripkaSer) March 14, 2016
kinda odd to talk down the AE profile vs other approved agents yet refuse to provide any context $GWPH
— zach (@zbiotech) March 14, 2016
$GWPH What's the point to hold a call when mgnt are not willing to give any color on secondary endpts, SAE details, etc...
— Andy Biotech (@AndyBiotech) March 14, 2016
$GWPH next 3 studies all larger...v imp for safety...this 1st dravet was ~120 pts
— zach (@zbiotech) March 14, 2016
1st LGS ~170 pts
2nd LGS ~225 pts
2nd dravet ~150 pts
To the $GWPH bio-twitter skeptics chiming in this morning — Is it really such a leap of logic to believe Epidiolex actually works?
— Adam Feuerstein (@adamfeuerstein) March 14, 2016
cowen '21 est of 700m in epidiolex incl 50m in dravet, 250m in LGS, and 400m in 'other pediatric epilepsies' $GWPH
— zach (@zbiotech) March 14, 2016
$GWPH CEO Gover on CNBC right now talking cannabidiol. Nothing new to the 100s of epilepsy families who've moved to Colorado in recent years
— David Maizenberg (@biologypartners) March 14, 2016
@AdamSinger @adamfeuerstein @bradloncar Folks are still skittish, but good to finally see a biotech - $GWPH - hold most of a big move.
— 23aloha (@23aloha) March 15, 2016
Celator goes "from 0 to hero" on positive AML data $CPXX
$CPXX Announces P3 for CPX-351 in Patients with High-Risk AML Demonstrates Stat Significant Improvement in OS https://t.co/dsf0tsOMcJ
— Daniel Ward (@danwardbio) March 14, 2016
$CPXX up 442%, from 0 to hero on OS data for myeloid leukemia --https://t.co/nW1DrEXvQl
— John Carroll (@JohnCFierce) March 14, 2016
$CPXX +400% in after hours. No typo!
— 23aloha (@23aloha) March 14, 2016
$CPXX breaks F-R rule - first time such a deep sub $300m mkt-cap company has done so - right @adamfeuerstein ?
— Red Acre Investments (@redacre) March 14, 2016
Leukemia & Lymphoma Society has invested $9.1m in Vyxeos to support P2&3 studies. LLS entitled to return of up to 3.55% from $CPXX.
— Mandy Jackson (@ScripMandy) March 15, 2016
$CPXX Surprises With Blood Cancer Drug Survival Benefit https://t.co/EaAJvwwTqu A Feuerstein-Ratain Rule exception!
— Adam Feuerstein (@adamfeuerstein) March 15, 2016
$CPXX Janney is really eager for some banking business, initiates overnight with $13 PT ;)
— Andy Biotech (@AndyBiotech) March 15, 2016
$CPXX 13G filed by Steve Cohen. 6.5% holder in Point72
— Shane Blackmon (@shaneblackmon) March 15, 2016
Steve Cohen disclosed a 2.8 million-share stake in a tiny pharmaceutical company that jumped 432% $CPXX https://t.co/YfiyMBJ2nf
— Biotech 5 (@Biotech_5) March 15, 2016
$CPXX - Steve Cohen’s Point72 says it has perfect U.S. compliance https://t.co/QswNHJntbP
— Bio Stocks™ (@BioStocks) March 18, 2016
It's the Ides of March for Valeant $VRX
VALEANT CEO: `CHALLENGES OF PAST FEW MONTHS NOT YET BEHIND US $VRX
— zach (@zbiotech) March 15, 2016
move the goalposts, ignore issues, and other fun things to pass the time...just file this $VRX report under 'another hot mess'
— zach (@zbiotech) March 15, 2016
$VRX says in investor presentation in cannot provide its "organic growth" metric "due to the ongoing review of company financials."
— Charley Grant (@CGrantWSJ) March 15, 2016
Psoriasis drug Pearson just referenced was abandoned by Amgen due in part to suicidal ideation side effect.
— Charley Grant (@CGrantWSJ) March 15, 2016
"Comfortable with our current liquidity" is up there with the least comfortable phrases on an earnings call $VRX
— Max Nisen (@MaxNisen) March 15, 2016
$VRX cratering another 18% pre-market on 2016 guidance. Will the analysts who defended the name change their tune?
— Downtown Josh Brown (@ReformedBroker) March 15, 2016
@megtirrell might be an overstatement. Time will tell whether anything really changed at all
— Michael Gladstone (@MikeNGladstone) March 15, 2016
Def the first time a company I've covered has cut guidance twice in one day □
— Drew Armstrong (@ArmstrongDrew) March 15, 2016
$VRX rues the day.
— CGB3 Beck (@princetongb) March 15, 2016
Ackman statement on $VRX: "We are going to take a much more proactive role at the co to protect and maximize the value of our investment" 1
— Meg Tirrell (@megtirrell) March 15, 2016
The fact that it's the Ides of March makes this Valeant situation absolutely perfect.
— Nathan Sadeghi-Nejad (@natesadeghi) March 15, 2016
I see $VRX support at 6.65 (Halloween 2008 low).
— CR (@CashRocket) March 15, 2016
@sport234a Some people think the entire prescription drug system is a house of cards based on headlines and $VRX doesn’t do that any favors.
— Brad Loncar (@bradloncar) March 16, 2016
$VRX didnt interest me at $150 $100 or $60
— Dan Rosenblum (@sharkbiotech) March 16, 2016
at $30 it interests me
ISI suspending rating on $VRX ... just can't trust the numbers
— Tyler (@TylerHCanalyst) March 16, 2016
Jefferies on $VRX: "All we can point to is 3rd party data (e.g., IMS Rxs) as evidence the co is real." EVIDENCE THE COMPANY IS REAL.
— Meg Tirrell (@megtirrell) March 16, 2016
$VRX Analysts Finally Wake UP
— Bio Stocks™ (@BioStocks) March 16, 2016
https://t.co/CryatTsWuP
Surprised I've only seen one person in my timeline buy $VRX
— Spartan Biotech (@SpartanBiotech) March 17, 2016
$VRX so much talk of debt restructuring but that only happens if they can't file the 10K in time. Something isn't adding up here.
— Erik Gudenas (@egudenas1) March 17, 2016
$VRX (+2.4% pre) Valeant CEO sends memo to employees assuring them the company isn't on the verge of bankruptcy https://t.co/Wf0mCeRdp4
— Open Outcrier (@OpenOutcrier) March 18, 2016
"Positive" data from Vitae Pharma fails to impress $VTAE
$VTAE Achieves Proof-of-Concept with RORyt Inhibitor in Moderate to Severe Psoriasis https://t.co/6clSNUbEw6 After hour 53% Up.
— Biopharminvest (@Biopharminvest) March 16, 2016
$VTAE Is interesting for a trade. Stock was $10 pre-EPS before worries about the trial. Would the stock be down 35% on these results? No.
— Shane Blackmon (@shaneblackmon) March 16, 2016
@VikramKhanna_ @shaneblackmon Otezla had PASI 50 at week 4 of 30%. $VTAE had 8.3%. Otezla had 0/263 patients with liver enzyme increases.
— Doceletaxel (@Doceletaxel) March 16, 2016
$VTAE track record so far-
— ABD (@outperformngpbo) March 17, 2016
Alz drug- discontinued, safety issues in PhI
Diabetes drug- discont., lack of efficacy
Psoriasis- iffy safety...
$VTAE last time we saw a stock pop on iffy safety was $AERI,down 45% from the highs once safety data detailed (and they haven't raised yet!)
— ABD (@outperformngpbo) March 17, 2016
As seen on the stream
The Cool Kids at SXSW Aren't Into Biotech. Here's Why. New @forbeshealth https://t.co/cvs7JRT9cC
— Luke Timmerman (@ldtimmerman) March 14, 2016
FDA: $gild has confirmed they are stopping 6 trials-Zydelighttps://t.co/0BYOLHwxJM
— Douglas Allan (@Dougallan1) March 14, 2016
$CPXX Wow... just like the good old days
— BioBreakout (@BioBreakout) March 14, 2016
A rare Mav rule - when SMID bio start playing buzzword bingo, run for the hills - it rarely works out well. What are they spinning? $RXDX
— Sally Church (@MaverickNY) March 15, 2016
Interesting and perhaps not entirely +ve that $LOXO anticipates resistance to 101 and has a next gen TRK inhbtr https://t.co/XT0IHXFWVA
— j l (@bio_clouseau) March 15, 2016
More $OREX news: partnership with $VRX to commercialize Mysimba in 18 Eastern & Central European countries + Turkey https://t.co/ZTncBKhpqa
— Meg Tirrell (@megtirrell) March 15, 2016
Seems like an ugly day brewing,intend to book what will likely amount to ~18% profit in $ITEK &track closely again.
— Jason (@JasonHolman5) March 15, 2016
$PETX says they are focused on getting non-dilutive funding from an ex-US partner. That’s obviously key given the current stock price.
— Brad Loncar (@bradloncar) March 15, 2016
$LLY sola - You don’t remove function as co-primary endpt if confident in trial outcome. Change says already risky trial even riskier.
— Adam Feuerstein (@adamfeuerstein) March 15, 2016
Some Biotech, Healthcare nLod$BIB $IBB $VRX $JUNO $GWPH$SRPT $VRTX $CELG $BXLT$CPXX $BIIB $ILMN $LLY $BLCM$MDVN $NVIV $PTCT $KITE $BLUE
— Tom Wrigley (@WrigleyTom) March 15, 2016
Lesson number #1: When your thesis is invalidated, put your ego aside, take the first loss & move on, 1st loss always your best loss... $VRX
— Jean Fonteneau (@JFinDallas) March 15, 2016
@mikegoodma the company would be steal at 10 -but I used to say under 20 lol
— Olddogwithnewtrix (@olddoggnewtrix) March 15, 2016
Per $esrx compounded drug utilization fell 55% YoY. Pretty impressive
— NathanAaron (@NathanAhron) March 15, 2016
$RLYP 1279 scripts feb 1-29 vs 564 jan
— j l (@bio_clouseau) March 15, 2016
Moderator at Roth Conference asking CEO of $TTPH to “handicap” ongoing discussions with the FDA. Sheesh, where do they find these guys?
— Dan Smithey (@dan_smithey) March 15, 2016
@bradloncar if this wasn't a bear market $RLYP would be in 20s - they have accomplished so much and are still heads-down executing. Amazing.
— Adam Singer (@AdamSinger) March 15, 2016
It's funny, I really don't remember any of my stocks going UP because $VRX used to be such hot shit.
— Tony Friedman (@zzlangerhans) March 15, 2016
@ColfaxCapital @BioTerp a 50% drop in VRX likely spilled over into biotech but imagine if VRX was included in IBB/XBI. Would've been worse
— BioBounce.com (@BioBounce) March 15, 2016
$MNKD 10-K mentions:
— Adam Feuerstein (@adamfeuerstein) March 15, 2016
“Going concern” 13 times
“Insolvency” 9 times
“Bankruptcy” 10 times
“Default” 22 times
Thanks again @SkepticalPhD for yet another productive & civil discussion of GT methods. $EDIT $SGMO et al #goodstuff
— Dr. Zoidberg (@psuvafan007) March 16, 2016
Dispute over cancer immunotherapy credit leads to corrections and questions about unfair competition. https://t.co/phrXzOAlUL
— Jeffrey Flier (@jflier) March 16, 2016
BioPharmCatalyst updates: $SPPI receive FDA Approval. $BIND Ph2 now due Apr + $AKAO $AVEO $CFRX $CLBS $ELTP $FBIO https://t.co/XbA62rH5zl
— BioPharmCatalyst (@crusadernz) March 16, 2016
LR $GILD core thesis in oncology was based combo of multiple kinase inhibitors (idelalisib)Nowcombination strategy is in tatters WHAT NEXT?
— dough (@tgtxdough) March 16, 2016
@Mazmasta btw, watching/trading that daily creep up on $EDIT?
— Tom Wrigley (@WrigleyTom) March 16, 2016
was strong yesterday on the bio smack-down as well.
Number of biotech charts back at looking quite awful once again, $VRTX just one of them that looks ready for break down... $CELG $BMRN $ALXN
— Jean Fonteneau (@JFinDallas) March 16, 2016
A telltale sign Biotech is hated is $CEMP reaching new 52-wk lows. Multiple successful P3s, great market, unmet need, but completely hated
— Dan Smithey (@dan_smithey) March 16, 2016
Jury ruled in favor of $AMGN, against $REGN $SNY in PCSK9 patent case, according to Mark Schoenebaum.
— Adam Feuerstein (@adamfeuerstein) March 16, 2016
The $PCSK9 patent decision hurts $REGN, helps $AMGN. But (1) Appeals will take years; (2) In short term, neither drug is selling.
— Matthew Herper (@matthewherper) March 16, 2016
Elizabeth Holmes and Mike Pearson are related: many cover stories about their "genius", believing their own BS --> Icarus like descent
— Bijan Salehizadeh (@bijans) March 16, 2016
Market's rallying but biotech isn't playing along.
— Charley Grant (@CGrantWSJ) March 16, 2016
Someone needs to create a medicine to help $IBB.
— Abby Nachtomi (@anachtomi) March 16, 2016
$VTAE open last 5.5 ... wonder hoe many people get burned thinking this will pull a $CPXX
— Steve Feffer (@sfef84) March 16, 2016
I/O at #AACR16$BMY CheckMate-141 HNSCC (early stoppage)$MRK Keytruda in MCC$JNJ VISTA$NVS TIM-3
— Andy Biotech (@AndyBiotech) March 16, 2016
Roche OX40$KITE/NCI MAGE-A3 TCR
@BioStockAddict If $GLPG is successful in both RA and CF it might have a chance of achievg its goal of becomg the leadg #EuropeanBiotech co.
— Schulz (@portefeuillefun) March 16, 2016
Biotech pricing issues make it the worst sector 2016. All spikes shortable except phase 3 data.
— John Welsh (@johnwelshtrades) March 17, 2016
$FLML Form 4 CEO buys 10k shares in open market #confidence. I might have sold that one a bit early. Been one of the few strong bio's here
— BioHunter (@TheBio_Hunter) March 17, 2016
Insider buying today in $rlyp $srpt $cmrx $sgen & $vvus.
— Joe (@Drchik23) March 17, 2016
#StPatricksDay takes on new meaning this year as half our companies are now domiciled there.
— Brad Loncar (@bradloncar) March 17, 2016
$SRPT up 6.5% in PM after the 3 insiders Form-4 bought 154,500 shares... just after the AdCom announcement https://t.co/O1zX1PJcKE
— Joe (@GantosJ) March 17, 2016
$GSK's Witty says right now w/ price debate we are sending " a signal to our kids its not cool to discover drugs" ...#pharma
— Sarah Karlin-Smith (@SarahKarlin) March 17, 2016
The $IBB (Biotech) is down more from its high now than it fell during the great recession.
— Ophir Gottlieb (@OphirGottlieb) March 17, 2016
Now: - 40%
Great Recession: - 33%
$HRTX ($15.80) & $ACAD ($18.80) for bounce plays soon..hmm.
— Sheff (@SheffStation) March 17, 2016
Ok is that a quadruple bottom in $xbi $ibb
— Pharm. D (@Pharmdca) March 17, 2016
Has $CPXX changed the rules? Maybe. $CYTR will be next to test the Feuerstein-Rattain rule. My review of the space https://t.co/oIW3xLFqas
— Robin Davison (@RobinDavison2) March 17, 2016
.@codytrades You know the drill. Sold half 48.10s and moved stop to entry. $XBI
— Cody (@codytrades) March 17, 2016
Biotech about to go green for St. Patrick's Day? $XBI $IBB
— 23aloha (@23aloha) March 17, 2016
$XBI green
— Brad Loncar (@bradloncar) March 17, 2016
@avidresearch Yep. Alz is high risk/reward. If approved probably gets bashed over pricing. Who wants to spend the next billions pursuing?
— Stan D'Andrea (@stanleydandrea) March 17, 2016
Best response to Evercore sentiment survey question "Has biotech bottomed?" -
— PropThink (@PropThinker) March 17, 2016
"Please soon"
@bradloncar $SAGE $XLRN $FGEN $ADRO down ~5%, $AFMD $TRIL $PETX $EPZM up a bunch, Odd.
— Dan Smithey (@dan_smithey) March 17, 2016
$cbay sold all at 2.2
— Pharm. D (@Pharmdca) March 17, 2016
I guess the algos can’t read beyond the $CBAY headline.
— Adam Feuerstein (@adamfeuerstein) March 17, 2016
$CBAY After Hours: 1.45 -0.25 (-14.71%) - as predicted..sell as fast as u can
— MAISA (@MaisaCorp) March 17, 2016
@rajramaswamy or "I've Been Beaten" $IBB
— Joe W. (@w_biltmore85) March 18, 2016
$EGRX — FDA rejected Kangio (RTU bivalirudin) https://t.co/OgW2BqUsAJ
— Adam Feuerstein (@adamfeuerstein) March 18, 2016
#Biotech Stock Mailbag: Sector Blues, $CPXX $MNKD $GWPH $VRX https://t.co/MOihRr2crw
— Bio Stocks™ (@BioStocks) March 18, 2016
wow a lot of peeps thinking #AACR16 abstract presentations are going to move their little stocks. Atmospheric inversion required first, imo.
— Paul D. Rennert (@PDRennert) March 18, 2016
$ORPN and HTBX have each gained more than 200% the day before their offerings priced. Common denominator: Roth Capital lead on offering
— Shane Blackmon (@shaneblackmon) March 18, 2016
@dsobek @JacobPlieth @PDRennert deaths and infections came out at ASH, remember writing about it. This latest is inevitable
— Sally Church (@MaverickNY) March 18, 2016
$sgyp hey at least they didn't PR after hours...
— RG Capital (@RyanEGerry) March 18, 2016
Biotech relief rally or trend change? Don't know yet, but 23 stocks are up 8% or more today, per finviz. $XBI $IBB
— 23aloha (@23aloha) March 18, 2016
Market looking good! Lots of bounce plays in effect! Good way to end the week.
— Sheff (@SheffStation) March 18, 2016